Annual Biomarkers Congress

Osaka | Japan   September 20-21, 2018

Call for Abstract

A biomarker or biological markers are naturally occurring molecule, gene, or characteristic by which a particular pathophysiological a natural process, disease, etc. can be identified or examined. For some biological state or condition, on biomarkers refer as a measurable indicator. In cell biology, a biomarker is a molecule that allows the observation and separation of a distinct cell, In genetics, a biomarker is a DNA sequence that causes disease and biomarkers are used to specify an exposure to or the impact of xenobiotics which are present in the environment and in organisms, in field of geology and astrobiology biomarkers are also used and also known as bio signatures. 

Biomarkers sanction the characterization of patient community and quantitation of the extent to which new drugs reach deliberated targets, alter suggested pathophysiological mechanisms and reach the clinical result. In genomics, the biomarker provocation is to point distinct molecular signatures in multiplex biological mixtures that can be unequivocal tally to biological events in order to endorse novel drug goal and forecast drug response. Biomarkers can stratify patient populations or quantify drug benefit in primary prevention or disease-modification studies in poorly served areas such as neuro decline and cancer. Clinically useful biomarkers are required to inform regulatory and therapeutic decision making regarding candidate drugs and their indications in order to help bring new medicines to the right patients faster than they are today.

  • Biomarkers and surrogate endpoints for clinical trials
  • Diagnostics and Biomarker development
  • Biomarkers as Part of the Clinical Development Process
  • Biomarkers and Veterinary Medicine

Biomarkers used in translational research, addressing the entire spectrum from discovery to evaluation and commercialization. Good Biomarker Sciences access to different lines of biomarker platforms that can be used to dissect the precise action of drugs or monitor patient’s health. From reviewing existing scientific data to full study design and optimization, throughout in-depth interpretation and recommendations, clinical trials.

Biomarkers inquire about takes a continuity that starts with exposure and extends through acceptance to the possible performance of biomarkers in a clinical surrounding. Biomarker disclosure needs high validity identifiable proof of biomarker applicants with simultaneous calculate data to display which proteins are altering to an authentic important degree in light of contamination. Biomarker competitors distinguished in exposure should be approved utilizing bigger example sets covering an expansive segment of patient companions.

The specialty of biomarker invention has displayed a great surge of interest in recent years. We can use biomarkers for many reasons including diagnosis, prognosis, and choosing suitable patient treatment, and can give data on disease mechanism. Translation of such markers to clinical testing include steps for their discovery and characterization, assay development, and finally, an application using automated podium working in clinical laboratories. With a target on protein-based biomarkers and clinical immunoassays, the three parts are a debate in greater point. The currently used technologies in the clinical laboratory are described, including ascribe of in.

A medical tool, which is often an in vitro tool and which provide data need a key for the safe and applicable use of a individual drug management or biological product is called a companion diagnostic. These tools help to decide whether a particular remedial product’s benefits to a patient will be of more help that can conceal any viable serious side effects or risks to treat a patient. These biomarkers congresses invite the latest technologies and techniques to be brought into the light. A partnership between cancer pharmaceutics and diagnostics is a sensitive relation as there is often accident due to lack of knowledge of requirements and feasibilities. The strategies for Rx-Dx partnerships provide a good platform for sharing the knowledge. Development of in-vitro companion diagnostic devices and their commercialization is a rapidly budding area. These diagnostics are useful in the study of surgical oncology.

Precision medicine depends on endorse biomarkers with which to satisfactory categorize victim by their predictable disease risk, prediction and/or response to treatment. Although inexpensive 'comics'-based technology has allowed faster identification of assumed biomarkers, the validation of biomarkers is still defeated by low mathematical power and poor productivity of results. This Review summarizes the successes and dare of using various types of the molecule as biomarkers, using lung cancer as a key representative example. Efforts at the national level of several countries to bind molecular assessment of specimen to patient data via electronic medical evidence are the future of precision medicine research.

Personalized medicine is a new field of research and evidence-based literature is required for integrating into healthcare delivery. Personalized medicine is known for its use of genomic information along with the family and lifestyle for a health management .accurate prediction made about a person susceptibility to developing the disease and course of the disease and response to the treatment.

  • Diagnosis and intervention
  • Drug development and usage
  • Cancer genomics
  • Challenges and probable solutions
  • Tumor biomarkers
  • Diagnostic and prognostic biomarkers

Biomarkers are key molecular or cellular events which link a specific environmental exposure to a health outcome. A biomarker is an appropriate tool which can be reasonably calculated and can act as a measure for physiological as well as pathological improvement to any therapeutic involvement. Classical biomarkers discover quantitative alteration in blood pressure; blood lactate levels post exercises, and blood glucose in diabetes mellitus. A biomarker, or bioindicator, for the most part, alludes to a quantifiable pointer of some organic state or condition. The term is additionally infrequently used to allude to a substance the nearness of which demonstrates the presence of a living being. Environmental Assessment also carried out in the natural or synthetic form as bio-monitoring. Encourage, life structures, life events for Interim analysis. Biomarkers are regularly measured and assessed to look at ordinary natural procedures, pathogenic procedures, or pharmacologic reactions to a restorative mediation

The indicative process of the presence of cancer in the body is referred as cancer biomarkers. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. There are different of cancer where biomarkers have its application such as lung, Melanoma, breast, Colorectal, Pancreas and many more. Biochemically, cancer biomarkers can be DNA, RNA, proteins, peptides, hormones, metabolites, and even biological processes such as apoptosis, angiogenesis or proliferation. There are three major types of cancer biomarkers based on their clinical use: prognostic, predictive, and pharmacodynamic markers.

Study of immune system biomarkers is called immunology biomarkers. Biomarkers discovery and discussed the framework for applying these concepts in the study of the immune system and its effects on the disease – cancer, infection, allergy, immunodeficiency, and autoimmunity. In biomarkers discovery, the immune system plays an important role since it interacts with all other systems in the human body and immune biomarkers are relevant for a large number of diseases.


Molecular Biomarkers is the biomarker that is in molecular form. These molecular biomarkers used in the processes of disease diagnosis, disease prognosis, prediction and calculation of the therapy response and the evaluation of the biomarkers. The molecular biomarkers are developed and validated to use it in drug development processes. Protein biomarkers, nucleic acid biomarkers, small molecule biomarkers, lipid biomarkers and micro RNA biomarkers are the example of biomarkers. The atomic biomarkers are only being created and approved to be utilized as a part of medical improvement and used to bolster endorsement of medication items.

·    Protein biomarker

·    Nucleic acid-based biomarkers

·    Small molecule biomarkers

·    Lipid biomarkers

·    microRNA biomarkers

The part of Biomarkers in medication declaration and advancement is to understand the physiopathology of a disorder. Biomarkers can be a clinical apparatus for medication revelation and upgrade by acceptability and security to the correct patient. Biomarkers can be utilized as a part of knowledge about the instrument of medication.

In the clinical trials process biomarkers are intended to replace surrogate endpoints. Surrogate markers are used to conduct the clinical trials and gather a no. of endpoints. The endpoint is impractical when the primary endpoint is undesired or the event number is small. The diagnostic and clinical development process biomarker helps much. Biomarkers case study plays an important role in finding a new treatment for the patients who need a new drug for various clinical practice.

  • Case reports on drug discovery
  • Case reports on imaging
  • Imaging biomarkers
  • Quantitative imaging biomarkers
  • Case reports on cancer biomarkers
  • Case reports on diagnostics

There is a revolution in the study of genomics and molecular biology DNA and RNA sequencing is rapid than the past strategy due to the Next-generation sequencing. Genetic-based biomarkers are the biomarkers involved in the process of representing gene and gene products. In the discovery of biomarkers, the genome sequencing using next-generation helps a lot.

  • Next-generation sequencing  for the discovery of biomarkers
  • Genome sequencing for the discovery of biomarkers
  • MicroRNA sequencing for the prediction of diseases
  • Using SNP as biomarkers
  • Genome biomarkers
  • Cell proliferation markers
  • Cytogenetic biomarkers
  • Oxidative stress biomarkers

Those putative biomarkers for Disease diagnosis and prognosis the complexity of structure and function of protein biomarkers and lack of high sensitivity, specificity, and reproducibility. The Food and drug administration has approved few biomarkers due to its advanced technology. The practical application of each protein separation or identification technique is analyzed using specific examples, Including four major application of immunology as ELISA, FACS, Western Blot and Immunoprecipitation. Mass spectrometers are unique which can directly analyze any biological molecule likely to be influenced to ionization. The biological studies of human metabolites and proteins using recent mass spectrometry technology (metabolomics and proteomics, respectively) have been ongoing for over a decade.